India mein AI startups ko le kar game badal raha hai. VC firms ab general AI models ke bajaye biotech aur enterprise automation jaise specific problems solve karne wale startups mein paisa laga rahi hain.
Global Venture Capital firms ab Indian AI startups mein paisa daal rahi hain, lekin khel ab thoda alag hai. Ab bade models ke peeche bhaagne ke bajaye, Peak XV Partners, Lightspeed, aur General Catalyst jaise bade investors un companies ko priority de rahe hain jo 'Agentic AI' bana rahi hain—matlab aisi software jo specific business tasks, jaise transaction workflows ya drug discovery, khud handle kar sake.
Specialized AI ka naya dor
Ab hype kam aur kaam zyada ki baat ho rahi hai. Ex-Zomato executive Rinshul Chandra apne naye venture ke liye $8–10 Million tak ki funding raise kar rahe hain jo merchant-side AI agents par focus karega. Dvar AI aur Erid Bio jaise startups bhi funding le rahe hain taaki enterprise compliance aur biological molecule design mein apni technology ko polish kar sakein. Ye companies chatbots ke saath compete karne ke bajaye existing enterprise software mein integrate hone ki koshish kar rahi hain.
Kya hai risk aur challenge?
Investors ko ye samajhna hoga ki yahan execution ka challenge bada hai. Enterprise-grade AI banane ke liye bahut zyada talent aur infrastructure par paisa kharch hota hai. In startups ko corporate clients ko ye prove karna padega ki unka software asli ROI (Return on Investment) de raha hai, varna competition unhe market se bahar kar dega.
Iske alawa, Data Privacy aur regulatory compliance bhi bade hurdle hain. Kyunki ye startups sensitive customer data handle kar rahi hain, zara si galti ya security breach hone par regulatory roadblocks aa sakte hain. Agar AI-driven automation ki demand utni tezi se nahi badhi jitna socha gaya hai, toh in companies ke cash flow par pressure aa sakta hai, jisse unki growth ruk sakti hai. Ab dekhna ye hoga ki ye startups prototype se nikal kar bade scale par enterprise implementation kaise karti hain.